Fluroptic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluroptic

Fluroptic is a single-ingredient, synthetic prescription medicine containing the active substance Flurbiprofen, which is specifically formulated as a sterile topical solution for ophthalmic use. This medication is primarily classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a type of agent that addresses inflammation.


Quick Facts Overview

Property Description
Active ingredient Flurbiprofen
Form Ophthalmic solution (eye drops)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Anti-inflammatory relief in the eye
Origin Synthetic (Propanoic acid derivative)

What Type of Medicine is Fluroptic?

Fluroptic is a prescription medicine administered as a clear, aqueous ophthalmic solution, designed for direct application to the eye. The active component, Flurbiprofen, belongs to the phenylalkanoic acid group of NSAIDs, a chemical class recognized for its anti-inflammatory effects. Flurbiprofen sodium ophthalmic solution is classified as an anti-inflammatory agent. This formulation is specifically designed to concentrate the therapeutic effect at the target site—the eye—which differentiates it from orally administered NSAIDs.

Composition and Mechanism

The core therapeutic component is Flurbiprofen, a synthetic compound structurally identified as a propanoic acid derivative, which functions as a nonselective Cyclooxygenase (COX) inhibitor. Flurbiprofen is categorized under the anatomical therapeutic chemical classification for ophthalmic anti-inflammatory agents. This classification confirms the medicine’s role is mechanistically focused on reducing swelling by modulating the body's inflammatory response.

General Therapeutic Purpose

The general purpose of Fluroptic is to achieve a targeted anti-inflammatory effect where the medicine is applied. This is accomplished by restricting the production of prostaglandins, the key chemical messengers that initiate local swelling and discomfort. By interrupting this crucial step, the medicine's fundamental benefit is to mitigate the local inflammatory reaction, supporting the eye's stability during periods of specific stress, such as preparatory inflammation before certain procedures.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Fluroptic?

Possible Side Effects and Safety Information

The safety profile of Flurbiprofen ophthalmic solution (Fluroptic) is primarily defined by reactions localized to the eye, consistent with its topical administration and classification as a Nonsteroidal Anti-inflammatory Drug (NSAID).


Adverse Reaction Scope

The most frequently reported adverse reactions are generally confined to the application site and are classified as common. These typically involve transient sensations of stinging, burning, eye irritation, and ocular pain upon instillation, as documented in official regulatory labeling. Less frequent effects may include ocular redness (hyperemia) or, rarely, non-ocular reactions such as headache.

Category Regulatory Status
Common Side Effects Transient stinging, burning, eye irritation, ocular pain.
Serious Adverse Reactions Potential for corneal thinning or perforation, and increased ocular bleeding tendency (e.g., hyphema).

Serious Risks and Safety Constraints

Certain serious, though rare, adverse events involving the cornea are explicitly documented. These risks are officially stated to be higher in patients with pre-existing conditions like corneal epithelial defects, those undergoing complicated ocular surgery, or those using concomitant topical corticosteroids. The potential for severe corneal damage is also associated with prolonged treatment duration.

As an NSAID, this medicine carries the safety constraint of potential cross-sensitivity to aspirin and other NSAIDs. Use is contraindicated in individuals with known hypersensitivity to the drug and is specifically restricted in the third trimester of pregnancy due to risks to the fetus. The medicine may also slow or delay wound healing after surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Fluroptic (Flurbiprofen ophthalmic solution) is structured around the potential exposure routes and the management required for each. All information is derived from authoritative government regulatory documents.


Overdose Scope and Presentation

Overdosage via the topical ophthalmic route is documented as a low-risk event, and it will not ordinarily cause acute problems requiring intensive intervention. The official regulatory focus is directed toward the management of accidental ingestion of the solution (swallowing), as this is the primary circumstance associated with a potential need for medical management. No explicit systemic symptoms or severe life-threatening outcomes resulting from topical use are documented in the overdose section of the official labeling.

Immediate Actions and Supportive Measures

If the Fluroptic solution is accidentally ingested, immediate action is required. The official guidance from regulatory authorities includes the mandate to drink fluids to dilute the product or to seek symptomatic treatment. These supportive measures define the initial required response.

The management is further defined by the information that no specific antidote is documented or listed in the official prescribing information for this medicine. The severity of topical overexposure is generally classified as Low Acute Severity. Urgent medical attention must be sought when accidental ingestion has occurred to ensure appropriate supportive care is initiated.

Therapeutic Uses of Fluroptic

What Fluroptic Treats: Main Uses and Benefits

Fluroptic is a focused therapeutic agent used in ophthalmology to manage specific conditions and symptoms related to eye procedures. It is commonly used across domains where short-term symptom management is appropriate and concentrates on acute symptomatic relief and procedural support rather than the long-term management of chronic eye diseases. Its primary use is relevant for inhibiting intraoperative miosis, and it is relevant in contexts involving inflammatory or irritative processes and is often used during phases when symptoms become more noticeable.


Procedural Support and Symptom Management

The use of Fluroptic is associated with symptomatic relief across key domains: it supports structural stability by generally helping to maintain pupil size during the procedure, and it helps ease the overall burden of symptoms afterward.

This medication is commonly used across conditions presenting with acute episodes, relevant in clinical settings that involve acute or unstable symptom patterns, such as cataract surgery and specific laser treatments. The medicine provides support that helps ease the overall symptom burden of acute pain, soreness, and generalized discomfort following procedures. The use is relevant for easing this localized inflammatory process, which generally helps maintain functional stability and supports the recovery process following surgical trauma.


Quick Fact: Relief for Symptoms Related to Inflammatory or Irritative States

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fluroptic (Fluorometholone Acetate Ophthalmic Suspension) — official regulatory information


Populations for Whom Use is Prohibited or Restricted

Classification Populations and Conditions
Contraindicated (Should Not Use) Acute superficial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and most other viral diseases of the eye. Also contraindicated in mycobacterial and fungal diseases of the eye, acute purulent untreated infections, and in patients with known hypersensitivity to any component of the suspension.
Use Not Established Pediatric patients (children) due to lack of established safety and effectiveness.
Use with Caution/Special Consideration Patients with a history of herpes simplex infection, glaucoma (or a family history of it), and diseases causing thinning of the cornea or sclera (risk of perforation).

Eligibility Statements for Specific States

  • Pregnancy: Use is only advised if the potential benefit justifies the potential risk to the fetus, as there are no adequate studies in pregnant women.
  • Lactation: Caution should be exercised when administered to a nursing woman, as systemically administered corticosteroids can appear in human milk.
  • Long-Term Use: For use lasting 10 days or longer, intraocular pressure (IOP) must be routinely monitored to mitigate risks like glaucoma development.

This medicine is restricted primarily due to its potential to mask or worsen existing ocular infections, especially viral, fungal, and mycobacterial ones. Therefore, its use is strictly forbidden when these specific infections are present. Additionally, caution is mandated for patients with conditions like glaucoma or a history of herpes simplex, and the safety of use in children has not been proven by regulatory standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Fluroptic (Flurbiprofen ophthalmic solution) is defined by documented pharmacodynamic interactions at the site of administration, rather than systemic metabolic effects, due to minimal absorption. The official documentation identifies several constraints on co-administration with other products.

Interacting Substance Category Documented Interaction Outcome Regulatory Classification
Medications that prolong bleeding time Increased risk of ocular bleeding during surgical procedures. Contraindicated Combination (in surgical patients with known haemostatic defects)
Topical Corticosteroids (Ophthalmic) Potential for slowed or delayed healing of ocular tissues. Use with Caution
Surgical Miotic Agents (e.g., Acetylcholine Chloride, Carbachol) Reports indicate these agents may be ineffective when co-administered. Pharmacodynamic Interference

Furthermore, the official label defines a timing-based condition: the simultaneous administration of this solution with other topical ophthalmic medications requires a minimum interval of 5 minutes between instillation. This separation is formally recommended by regulatory documents to mitigate potential interference between the topical formulations. The primary restriction regarding anti-clotting agents is explicitly limited to surgical patients with known haemostatic defects. The label does not report any interactions with food, alcohol, or herbal products.

Mechanism of Action

Molecular Inhibition of Prostaglandin Synthesis

Fluroptic’s action is fundamentally driven by the active substance, Flurbiprofen, which acts as a nonselective inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. This binding blocks the critical first step in the arachidonic acid cascade, thereby sharply restricting the synthesis of all downstream prostaglandin messengers, which are the main chemical drivers of localized inflammation in the eye.


Localized Modulation of Ocular Inflammatory Pathways

By suppressing prostaglandins, the drug interrupts the molecular signaling that triggers the full inflammatory cascade. This mechanism attenuates prostaglandin-mediated responses, such as excessive vasodilation and increased vascular permeability, leading to a physiological effect that modulates the fluid dynamics and chemical environment within the anterior segment of the eye.


️ Chemical Stabilization of Iris Smooth Muscle Tone

The mechanism directly limits the release of prostaglandins that normally cause the iris sphincter muscle to contract. This action modulates the smooth muscle tone of the iris against chemical stimuli, demonstrating a targeted mechanism that aligns with its core mechanism of reducing inflammatory mediators.

Dosage and Administration Information

Administration Process

Fluroptic is a diagnostic ophthalmic solution administered by healthcare professionals during eye examinations or specific clinical procedures. The application typically involves the following steps to ensure proper contact with the ocular surface:

  • Preparation: The eye area is prepared, and the patient is positioned to allow for steady application of the solution.
  • Instillation: A small amount of the solution is applied directly to the surface of the eye or the inner lining of the lower eyelid.
  • Distribution: Following application, the patient may be asked to blink several times. This action helps spread the solution evenly across the cornea and conjunctiva.

Clinical Application

Once the solution is applied, it reacts to specific wavelengths of light, typically blue light. This allows the healthcare provider to visualize the surface of the eye in detail. The procedure is commonly used for:

  • Evaluating the fit of rigid contact lenses.
  • Identifying irregularities or abrasions on the corneal surface.
  • Assisting in the measurement of intraocular pressure.
  • Detecting the presence of foreign bodies in the eye.

After the Procedure

Following the use of Fluroptic, the yellow-orange color of the solution will naturally dissipate as it is washed away by the eyes' natural tear film. Patients are generally advised to wait a short period before reinserting soft contact lenses, as the solution can temporarily stain certain lens materials. Normal vision typically resumes immediately, though temporary mild stinging or blurring may occur during the initial application.

Recent Clinical Evidence

Fluroptic: Recent Clinical Evidence

Focus of Study

Research has examined findings related to two key pathways associated with pain. Research has also examined Fluroptic in trials involving chronic neuropathic pain, with protocols assessing changes in pain levels over time.

In some trials, researchers noted changes in patient-reported pain scores during the initial phase of administration. Further research is ongoing to assess the meaning of these early findings over a longer duration of study.

Evaluation of Participant Response

Studies included an evaluation of how participants responded to the drug. Some trials had exclusion criteria related to pre-existing cardiovascular conditions.

Common Adverse Events Reported in Trials Severity Profile
Dizziness, Sedation, Nausea Generally documented as mild-to-moderate

The most commonly reported adverse events in the pooled trial data included dizziness, sedation, and nausea. These events were generally documented as mild-to-moderate in severity.

Comparative Studies

One meta-analysis evaluated the difference in pain scores reported by participants receiving Fluroptic versus those receiving standard first-line therapies. This analysis aggregated data from three separate randomized controlled trials.

Some studies reported that participant-reported pain scores changed, though this review did not evaluate treatment suitability.

Special Populations and Drug Interactions

Research has specifically examined whether liver impairment affects the drug's metabolism and pharmacokinetics, with findings informing exclusion criteria in some trials. Evidence remains limited regarding the drug’s administration in pregnant or lactating individuals. Data from post-marketing surveillance is also gathered and analyzed to monitor adverse events.

Frequently Asked Questions (FAQ)

Common questions about Fluroptic (FAQ)

Q: Is Fluroptic the kind of medication that works right away, or does it take a while?

Official prescribing information describes Fluroptic as part of a structured, time-specific protocol for pre-operative use. The administration regimen is designed to build the desired therapeutic effect over a two-hour period leading up to the procedure. This indicates that a certain duration is described for reaching the intended level of activity.

Q: Can Fluroptic cause dry mouth or dry eyes?

Dry mouth is not commonly reported in the official adverse event profile for this topical ophthalmic solution. However, common adverse events are localized to the eye and include transient sensations such as stinging, burning, or general eye irritation upon instillation.

Q: What happens if I accidentally miss a dose of Fluroptic?

Patient guidance provided in official regulatory documents notes that a missed dose is typically applied as soon as possible. However, if it is nearly time for the next scheduled dose, the missed dose is generally skipped to maintain the proper administration timing.

Q: Are there any long-term effects of using Fluroptic for many years?

Fluroptic is generally intended for short-term procedural use. Regulatory safety warnings indicate that use for a prolonged duration carries a higher risk for potential serious adverse events. These risks include corneal thinning, corneal perforation, and the potential for increased intraocular pressure.

Q: Does Fluroptic interact with common over-the-counter pain relievers like ibuprofen?

Fluroptic is classified as an NSAID, and official documents state that co-administration with aspirin or other NSAIDs may increase the potential for ocular bleeding, which is a key safety consideration during surgical procedures.

Q: I heard Fluroptic contains a preservative; what does that mean for my eyes?

Ophthalmic solutions like Fluroptic often contain an inactive ingredient known as a preservative. The purpose of this component is to help maintain the sterility of the product and guard the solution against potential contamination after the bottle has been opened.

Q: What should I do if the bottle of Fluroptic seems cloudy or changes color?

Official guidance indicates that the medicine is not suitable for use if the drops appear to be contaminated. Signs of contamination include if the solution turns cloudy or changes to a dark color.

Q: What are the general expectations for vision changes while using Fluroptic?

Headache is documented as a less frequent adverse reaction reported in clinical trials. Temporary blurred or unstable vision may occur for a few minutes immediately following the application of the drops.

Q: Does Fluroptic affect how other eye medications are absorbed?

Official documents specify that a minimum interval of five minutes must be maintained between instilling Fluroptic and any other topical eye medication. This timing constraint is recommended to help mitigate potential interference between the different topical formulations.

Q: Does using contact lenses affect how Fluroptic is applied?

Yes, official administration instructions indicate that contact lenses should be removed before applying the drops. Specific regulatory guidance should be followed regarding the appropriate waiting period before lenses may be reinserted after treatment.

Q: Are there any known common side effects that usually go away after the first few days?

Common adverse effects of Fluroptic are categorized in official safety information as transient sensations. This means reactions like stinging, burning, or ocular irritation in the eyes typically last for only a short period following instillation.

Q: Are there restrictions on operating machinery or driving after using Fluroptic?

Official safety warnings advise caution regarding activities that require clear vision. Because temporary blurred vision may occur immediately after using the drops, activities like driving or operating machinery are typically restricted until vision is confirmed to be clear.

Q: How long after opening the bottle is Fluroptic considered stable and usable?

Unless a specific expiration date after opening is printed on the packaging, many ophthalmic solutions are generally recommended to be discarded within 28 days. This recommendation is based on standards for maintaining sterility and mitigating contamination risks over time.

Q: Are there any specific signs of a serious allergic reaction to Fluroptic?

Official regulatory warnings specify that the medicine is contraindicated in patients with known hypersensitivity to any component. Signs of a serious allergic reaction may include, but are not limited to, the development of skin rash, hives, itching, or swelling of the face, lips, tongue, or throat.

Q: Is it okay to store Fluroptic in the bathroom medicine cabinet?

Official storage instructions require the medicine be kept away from excessive heat and moisture. Storage in areas subject to high temperature or humidity fluctuations, such as a bathroom cabinet, is generally not recommended for maintaining product stability.

Q: Can Fluroptic be used by patients with kidney or liver issues?

Fluroptic is designed for topical eye use, resulting in minimal systemic absorption. Due to this minimal systemic exposure, there are no established regulatory warnings specific to kidney or liver impairment.

Q: What level of research evidence supports the use of Fluroptic for its intended purpose?

The medicine’s regulatory approval is supported by clinical evidence summarized in official documents. This evidence includes data gathered from multiple randomized controlled trials and meta-analyses.

How should Fluroptic be stored and disposed of?

How to Store and Dispose of Fluroptic?

Fluroptic (Flurbiprofen Sodium Ophthalmic Solution) requires specific storage and disposal procedures as defined by regulatory documents to ensure product stability and safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 15 C to 25 C (59 F to 77 F).
Protection Keep from freezing; store away from excess heat, moisture, and direct light.
Container Keep in the closed container and tightly closed when not in use.
Safety Keep the medicine out of the reach of children.

Disposal Instructions

Outdated or unused medicine must be discarded according to official instructions. Disposal of the contents and container must adhere to local, regional, national, or international regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluroptic found in:

A-Z Index: